Loading
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Regular session
$3.27
+$0.01 · +0.31%
Regular session · ET · Market data may be delayed.
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Day range
Current $3.27
52-week range
Current $3.27
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
82
Deep Value
Sentiment
45
Mixed
Risk
50
Elevated Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Day range
Current $3.27
52-week range
Current $3.27
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 407.32M USD | 333.62M USD | 124.46M USD | 52.16M USD | 10.1M USD |
| Cost of goods sold | 42.6M USD | 50.56M USD | 17.8M USD | 4.12M USD | 1M USD |
| Gross profit | 364.72M USD | 283.06M USD | 106.66M USD | 48.04M USD | 9.1M USD |
| Research and development | 68.47M USD | 52.32M USD | 35.54M USD | 35.2M USD | 91.14M USD |
| Selling, general, and administrative | 337.23M USD | 258.69M USD | 134.4M USD | 76.6M USD | 72.3M USD |
| Operating expenses | 405.7M USD | 311.01M USD | 169.94M USD | 111.8M USD | 163.44M USD |
| Interest expense | 28.4M USD | 20.09M USD | 8.87M USD | 5.07M USD | 4.5M USD |
| Depreciation and amortization | 3.06M USD | 2.06M USD | 1.29M USD | 1.14M USD | 2.81M USD |
| Operating income | −40.98M USD | −27.95M USD | −63.28M USD | −63.76M USD | −154.35M USD |
| Net income | −61.6M USD | −39.14M USD | −66.07M USD | −67.21M USD | −158.17M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$13.00
297.55% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 20, 2021 | 4:1 | — | — |
Effective Jul 20, 2021
4:1
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI27.99M0.00%2.3T USD0.03%$379.12-0.50%
State Street SPDR S&P Biotech ETFXBI24.37M0.24%10.08B USD0.35%$149.1-0.75%
iShares Russell 2000 ETFIWM20.82M0.03%78.56B USD0.19%$277.09-0.22%
Vanguard Extended Market ETFVXF10.82M0.01%95.4B USD0.05%$232.88-0.26%
Invesco Biotechnology & Genome ETFPBE10.1M2.45%412.1M USD0.59%$94.02-0.85%
iShares Russell 2000 Growth ETFIWO7.41M0.05%14.25B USD0.24%$352.84-0.71%
Vanguard Russell 2000 ETFVTWO5.31M0.03%18B USD0.06%$111.93-0.25%
Schwab U.S. Small-Cap ETFSCHA4.35M0.02%21.7B USD0.03%$32.575-0.11%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFInvesco Biotechnology & Genome ETFPBEiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
